Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bruzzi

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 11, 2021
Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patientsGiuseppe Canavese, Corrado Tinterri, Franca Carli, et al.
Oncotarget|April 2, 2016
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patientsPaola Griseri, Ornella Garrone, Alessandra Lo Sardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patientsPaolo Bruzzi, Lucia Del Mastro, Maria P Sormani, et al.
Oncology|July 7, 2020
Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700)Marco Carlo Merlano, Nerina Denaro, Stefania Vecchio, et al.
Cancer|July 19, 2002
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinomaGiorgio Cocconi, Beatrice Di Blasio, Corrado Boni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 22, 2011
CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatusMałgorzata Mikulska, Anna Maria Raiola, Paolo Bruzzi, et al.
Journal of Neurology|July 16, 2005
The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosisMaria Pia Sormani, Paolo Bruzzi, Karola Beckmann, et al.
Journal of Translational Medicine|May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
International Journal of Cancer|October 24, 2008
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapiesNicola Tinari, Rossano Lattanzio, Patrizia Querzoli, et al.
Cancers|August 6, 2020
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision AnalysisGiuseppe Cabibbo, Ciro Celsa, Marco Enea, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 11, 2021
Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patientsGiuseppe Canavese, Corrado Tinterri, Franca Carli, et al.
Oncotarget|April 2, 2016
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patientsPaola Griseri, Ornella Garrone, Alessandra Lo Sardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patientsPaolo Bruzzi, Lucia Del Mastro, Maria P Sormani, et al.
Oncology|July 7, 2020
Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700)Marco Carlo Merlano, Nerina Denaro, Stefania Vecchio, et al.
Cancer|July 19, 2002
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinomaGiorgio Cocconi, Beatrice Di Blasio, Corrado Boni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 22, 2011
CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatusMałgorzata Mikulska, Anna Maria Raiola, Paolo Bruzzi, et al.
Journal of Neurology|July 16, 2005
The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosisMaria Pia Sormani, Paolo Bruzzi, Karola Beckmann, et al.
Journal of Translational Medicine|May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
International Journal of Cancer|October 24, 2008
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapiesNicola Tinari, Rossano Lattanzio, Patrizia Querzoli, et al.
Cancers|August 6, 2020
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision AnalysisGiuseppe Cabibbo, Ciro Celsa, Marco Enea, et al.
Pageof 16